Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

First International Summit on Interventional Pharmacoeconomics

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Amit Sanyal, MD: A Clinician’s Perspective

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Dec

Today In Oncology

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Amit Sanyal, MD: A Clinician’s Perspective

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Outcomes Associated With Consensus Molecular Subtypes in First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer

Addition of Pirfenidone to Glucocorticoids in Grade 2 or 3 Radiation-Induced Lung Injury

Lung Cancer Screening Criteria NELSON vs PLCOm2012

ADCs vs Standard Chemotherapy: Cardiotoxicity in HER2-Positive Advanced Breast Cancer

Exploratory FLAURA2 Analysis Confirms Overall Survival Benefit for Osimertinib in NSCLC Subgroups